Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sino Biopharmaceutical ( (HK:1177) ) has issued an update.
Sino Biopharmaceutical Limited announced the successful results of their phase III clinical study at the 2025 ASCO Annual Meeting, showcasing the efficacy of benmelstobart injection combined with anlotinib hydrochloride capsules as a first-line treatment for PD-L1 positive advanced non-small cell lung cancer (NSCLC). The study, known as CAMPASS, demonstrated a significant improvement in progression-free survival (PFS) compared to pembrolizumab, with a notable 6.1-month prolongation in median PFS and a 40% reduction in the risk of disease progression or death in patients with TPS ≥50%. This advancement is expected to enhance first-line treatment options for PD-L1 positive advanced NSCLC patients in China, marking a significant clinical value in the oncology field.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands, focusing on the biopharmaceutical industry. It specializes in developing and marketing pharmaceutical products, particularly in the area of oncology, and aims to provide innovative treatment options for patients.
Average Trading Volume: 104,392,293
Technical Sentiment Signal: Buy
Current Market Cap: HK$78.69B
For an in-depth examination of 1177 stock, go to TipRanks’ Stock Analysis page.